Table 1. Screening prior to CAR T-cell... | American Society of Hematology

Table 1.

Screening prior to CAR T-cell

Viral	Bacterial	Fungal	Parasitic
*Everyone:* Hepatitis B Hepatitis C HIV Respiratory viral panel (including COVID-19)^a *Considered^b: CMV EBV HTLV-1 Rarely done*^c: HSV-1 HSV-2 VZV	*Considered^b:* Treponema pallidum Mycobacterium tuberculosis	*Considered*^b: Beta-D-glucan Aspergillus Coccidioides Histoplasma Cryptococcus	*Considered^b: Strongyloides stercoralis* Toxoplasma gondii

Viral	Bacterial	Fungal	Parasitic
*Everyone:* Hepatitis B Hepatitis C HIV Respiratory viral panel (including COVID-19)^a *Considered^b: CMV EBV HTLV-1 Rarely done*^c: HSV-1 HSV-2 VZV	*Considered^b:* Treponema pallidum Mycobacterium tuberculosis	*Considered*^b: Beta-D-glucan Aspergillus Coccidioides Histoplasma Cryptococcus	*Considered^b: Strongyloides stercoralis* Toxoplasma gondii

This practice varies across institutions; should be performed in all symptomatic patients.

Asymptomatic screening should be considered during high influenza and COVID-19 seasons.

Considered in higher-risk patients such as those with recent BMT/prolonged steroid use/BCMA-CAR-T (for CMV), and endemic area exposure or for recent infection (for mycobacterium, fungal, and parasitic screening).

May be tested in rare scenarios where HSV/VZV prophylaxis is not universally offered.

HTLV, human T-lymphotropic viruses.

View Large

This Feature Is Available To Subscribers Only